We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

More Anglo, less Swedish

10 April 2012 By Chris Hughes

Investors are frustrated with the Anglo-Swedish pharma group’s shrinking collection of blockbuster drugs. It’s time for a major strategic review, led by an active leader willing to tackle taboo topics. There’s an opportunity – a new chair is set to be approved later this month.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)